Bio-Connect

BUB3 antibody [N1C1]

GTX113595
GeneTex
ApplicationsImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetBUB3
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    BUB3 antibody [N1C1]
  • Delivery Days Customer
    9
  • Antibody Specificity
    IP/MS validation was supported by references (PMID:30377413)
  • Application Supplier Note
    WB: 1:500-1:3000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.32 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID9184
  • Target name
    BUB3
  • Target description
    BUB3 mitotic checkpoint protein
  • Target synonyms
    BUB3 budding uninhibited by benzimidazoles 3 homolog; BUB3L; budding uninhibited by benomyl; budding uninhibited by benzimidazoles 3 homolog; hBUB3; mitotic checkpoint component; mitotic checkpoint protein BUB3; testicular tissue protein Li 27
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDO43684
  • Protein Name
    Mitotic checkpoint protein BUB3
  • Scientific Description
    This gene encodes a protein involved in spindle checkpoint function. The encoded protein contains four WD repeat domains and has sequence similarity with the yeast BUB3 protein. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq]
  • Reactivity
    Human, Mouse, Rat
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • A high-throughput pipeline for validation of antibodies. Sikorski K et al., 2018 Nov, Nat Methods
    Read more
  • Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer. Chang JF et al., 2014 Jun, Toxicol Sci
    Read more